Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Chronic cough stories

Jul 17, 2026

GSK halts development of chronic cough drug after late-stage trial failures

GSK discontinued development of an experimental chronic cough treatment after it failed to meet key goals in two late-stage clinical trials, with the company stating it was unlikely to transform patient care. Shares fell about 4%.

Jul 17, 2026·2 sources
00

Top claims

  • ▪GSK will halt the development of its experimental drug, camlipixant, for treating refractory chronic cough
  • ▪GSK had forecasted peak annual sales of about £2.5 billion for camlipixant, though analyst estimates were closer to £1 billion
  • ▪Following the announcement on July 17, 2026, GSK's shares fell by as much as 4.5%

Topics

Clinical trialsPharmaceutical IndustryDrug Approval and Clinical Trials